Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer.

Autor: He K; Department of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Barsoumian HB; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Puebla-Osorio N; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hu Y; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sezen D; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Radiation Oncology, Koç University School of Medicine, Istanbul, Turkey., Wasley MD; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bertolet G; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang J; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Leuschner C; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yang L; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kettlun Leyton CS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fowlkes NW; Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas., Green MM; Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hettrick L; Ionis Pharmaceuticals, Carlsbad, California., Chen D; Department of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, China., Masrorpour F; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gu M; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Maazi H; Ionis Pharmaceuticals, Carlsbad, California., Revenko AS; Ionis Pharmaceuticals, Carlsbad, California., Cortez MA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Welsh JW; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Publikováno v: Cancer immunology research [Cancer Immunol Res] 2023 Apr 03; Vol. 11 (4), pp. 486-500.

Bone morphogenetic protein 7 promotes resistance to immunotherapy.

Autor: Cortez MA; Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. MACortez@mdanderson.org., Masrorpour F; Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ivan C; Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang J; Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Younes AI; Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lu Y; Epigenetic and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Estecio MR; Epigenetic and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Barsoumian HB; Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Menon H; Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Caetano MDS; Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ramapriyan R; Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Schoenhals JE; Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang X; Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Skoulidis F; Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wasley MD; Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Calin G; Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hwu P; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Welsh JW; Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Publikováno v: Nature communications [Nat Commun] 2020 Sep 24; Vol. 11 (1), pp. 4840. Date of Electronic Publication: 2020 Sep 24.